EDGAR 10-K Filing

Company CIK: 1538495
Filing Year: 2024
Filename: 1538495_10-K_2024_0001493152-24-025578.json

---

ITEM 1. BUSINESS
ITEM 1. BUSINESS
BUSINESS BACKGROUND AND OVERVIEW
Earth Science Tech, Inc. (“ETST” or the “Company”) was incorporated under the laws of the State of Nevada on April 23, 2010. The Company subsequently changed its domicile to the State of Florida on June 27, 2022. As of November 8, 2022, the Company is a holding entity set to acquire companies with its current focus in the health and wellness industry. The Company is presently in compounding pharmaceuticals and telemedicine through its wholly owned subsidiaries RxCompoundStore.com, LLC. (“RxCompound”), Peaks Curative, LLC. (“Peaks”), and Earth Science Foundation, Inc. (“ESF”).
RxCompound is a complete compounding pharmacy. RxCompound is currently licensed to fulfill prescriptions in 22 states: Delaware, Florida, Pennsylvania, New York, Arizona, New Jersey, Wisconsin, Minnesota, Rhode Island, Utah, Georgia, Nevada, Massachusetts, Missouri, Iowa, Maryland, Ohio, Colorado, North Carolina, Maine, Indiana and Illinois. RxCompound is in the application process to obtain licenses in the remaining states in which it is not yet licensed to fulfill prescriptions.
Peaks is a telemedicine referral site focused on overall health and wellness for men and women. Peaks’ orders are exclusively fulfilled by RxCompound. Patients who order Peaks via monthly subscription receive their refills automatically. The company intends to expand offerings to include over the counter (“OTC”) (non-prescription) products such as supplements and topicals.
ESF is a favored entity of ETST, effectively being a non-profit organization that was incorporated on February 11, 2019, and is structured to accept grants and donations to help those in need of assistance in paying for prescriptions.
Current Operations
CORPORATE STRATEGY
The Company currently operates as a holding entity with a presence in the telehealth and compounding pharmaceutical sectors. Its primary objective is to deliver contemporary and personalized health and wellness medications to patients.
PRODUCT REGULATION
As a consumer-driven healthcare organization, we are required to comply with complex healthcare laws and regulations at both the state and federal level.
Marketing
Peaks’ marketing strategy relies on a combination of social media and search advertising techniques to reach its target audience effectively.
RxCompound has garnered a remarkable reputation through positive word-of-mouth, owing to its innovative approaches and unwavering commitment to quality.
COMPETITION
The Company’s competitors are other Specialty Compounding Pharmacies in the markets in which the subsidiaries operate and any telehealth platforms with a presence in overall health for men and women.
EMPLOYEES
As of March 31, 2024, the Company has thirty-two employees. None of our employees are represented by a union or covered by a collective bargaining agreement. We have not experienced any work stoppages, and we consider our relationship with our employees to be good.

---

ITEM 1A. RISK FACTORS
ITEM 1A. RISK FACTORS
A description of the risks and uncertainties associated with our business and ownership of our Class A common stock is set forth below. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The occurrence of any of the events or developments described below could materially and adversely affect our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our Class A common stock could decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See “Cautionary Note Regarding Forward-Looking Statements.”
Summary of Principal Risk Factors
● Our limited operating history and evolving business make it difficult to evaluate our current business and future prospects and increase the risk of your investment.
● Our results of operations, as well as our key metrics, may fluctuate on a quarterly and annual basis, which may result in our failing to meet the expectations of industry and securities analysts or our investors.
● If we are unable to expand the scope of our offerings, including the number and type of products and services that we offer, the number and quality of healthcare providers serving our customers, and the number and types of conditions capable of being treated through our platform, our business, financial condition, and results of operations may be materially and adversely affected.
● If we are unable to successfully market to new customers and retain existing customers, or if evolving privacy, healthcare, or other laws prevent or limit our marketing activities, our business, financial condition, and results of operations could be harmed.
● We operate in highly competitive markets and face competition from large, well-established healthcare providers and more traditional retailers and pharmaceutical providers with significant resources, and, as a result, we may not be able to compete effectively.
● Our brand is integral to our success. If we fail to effectively maintain, promote, and enhance our brand in a cost-effective manner, our business and competitive advantage may be harmed.
● Our pharmacy business subjects us to additional healthcare laws and regulations beyond those we face with our core telehealth business and increases the complexity and extent of our compliance and regulatory obligations.
● If we fail to comply with applicable healthcare and other governmental regulations, we could face substantial penalties, our business, financial condition, and results of operations could be adversely affected, and we may be required to restructure our operations.
● Evolving government regulations and enforcement activities may require increased costs or adversely affect our results of operations.
● Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or customers or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
● We may be subject to legal proceedings and litigation, including intellectual property disputes, which are costly to defend and could materially harm our business and results of operations.
● We may require additional capital to support business growth, and this capital might not be available on acceptable terms, if at all.
● Our Series B class Preferred stock structure has the effect of concentrating voting power with our Chief Executive Officer and Director, Giorgio R. Saumat, which limits an investor’s ability to influence the outcome of important transactions, including a change in control.
● The market price of our common stock may be volatile.
Risks Related to Peaks and RxCompound Business
Our limited operating history and evolving business make it difficult to evaluate our current business and future prospects and increase the risk of your investment.
If we are unable to expand the scope of our offerings, including the number and type of products and services that we offer, the number and quality of healthcare providers serving our customers, and the number and types of conditions capable of being treated through our platform, our business, financial condition, and results of operations may be materially and adversely affected.
If we are unable to successfully market to new customers and retain existing customers, or if evolving privacy, healthcare, or other laws prevent or limit our marketing activities, our business, financial condition, and results of operations could be harmed.
Use of social media and celebrity influencers may materially and adversely affect our reputation or subject us to fines or other penalties.
Our brand is integral to our success. If we fail to effectively maintain, promote, and enhance our brand in a cost-effective manner, our business and competitive advantage may be harmed.
The failure of our offerings to achieve and maintain market acceptance could result in our achieving revenue below our expectations, which could cause our business, financial condition, and results of operations to be materially and adversely affected.
The market for Peaks’ business model and services is new, rapidly evolving, and increasingly competitive, as the healthcare industry in the United States is undergoing significant structural change and consolidation, which makes it difficult to forecast demand for our solutions.
Competitive platforms or other technological breakthroughs for the monitoring, treatment, or prevention of medical conditions may adversely affect demand for our offerings.
We operate in highly competitive markets and face competition from large, well-established healthcare providers and more traditional retailers and pharmaceutical providers with significant resources, and, as a result, we may not be able to compete effectively.
The activities and quality of healthcare providers treating Peaks’ customers and providing prescriptions to RxCompound, including any potentially unethical or illegal practices, could damage our brand, subject us to liability, and harm our business and financial results.
Any failure to offer high-quality support may adversely affect the Company’s relationships with customers and healthcare providers, and in turn the Company’s financial condition, and results of operations.
Acquisitions and investments could result in operating difficulties, dilution, and other harmful consequences that may adversely impact the Company, financial condition, and results of operations. Additionally, if the Company is not able to identify and successfully acquire suitable businesses, the Company, results of operations, and prospects could be harmed.
Economic uncertainty or downturns, particularly as it impacts the healthcare industry, could adversely affect the Company’s business, financial condition, and results of operations.
If Peaks is unable to deliver a rewarding experience on mobile devices, Peaks may be unable to attract and retain customers.
Peaks’ business depends on continued and unimpeded access to the internet and mobile networks.
We depend on a number of other companies to perform functions critical to Peaks’ ability to operate its platform and RxCompound’s ability to offer services, generate revenue from customers, and to perform many of the related functions.
Disruption in the Company’s supply chain could negatively impact our business.
The Pharmacy business subjects the Company to additional healthcare laws and regulations beyond those that Peaks faces with its core telehealth business, and RxCompound’s services increase the complexity and extent of compliance and regulatory obligations.
The Company’s payments system depends on third-party service providers and is subject to evolving laws and regulations.
The Company’s pricing decisions may adversely affect our ability to attract new customers, healthcare providers, and other partners.
The Company’s success depends on the continuing and collaborative efforts of its management team, and its business may be severely disrupted if the company loses their services.
We depend on the Company’s talent to grow and operate its business, and if unable to hire, integrate, develop, motivate, and retain personnel, the Company may not be able to grow effectively.
The Company’s inventory is stored in RxCompound’s facility located in Miami, FL, and any damage or disruption at the facility may harm the business.
Risks Related to Governmental Regulation
If the Company fails to comply with applicable healthcare and other governmental regulations, we could face substantial penalties, our business, financial condition, and results of operations could be adversely affected, and we may be required to restructure our operations.
If Peaks or RxCompound’s practices are found to violate federal or state anti-kickback, physician self-referral, or false claims laws, the Company may incur significant penalties and reputational damage that could adversely affect our business.
Evolving government regulations and enforcement activities may require increased costs or adversely affect the Company’s results of operations.
Changes in public policy that mandate or enhance healthcare coverage could have a material adverse effect on the business, operations, and/or results of operations.
The products Peaks and RxCompound sell are subject to FDA regulations and other international, federal, state, and local requirements, and if the Company fails to comply with international, federal, state, and local requirements, Peaks and RxCompound’s ability to fulfill customers’ orders through our platform could be impaired.
Peaks and RxCompound may be subject to fines, penalties, and injunctions if we are determined to be promoting the use of products for unapproved uses.
The information that Peaks and RxCompound provide to healthcare providers, customers, and partners could be inaccurate or incomplete, which could harm the business, financial condition, and results of operations.
Peaks and RxCompound use, disclosure, and other processing of personally identifiable information, including health information, is subject to federal, state, and foreign privacy and security regulations, and failure to comply with those regulations or to adequately secure the information held could result in significant liability or reputational harm and, in turn, a material adverse effect on customers, providers, and revenue.
Public scrutiny of internet privacy and security issues may result in increased regulation and different industry standards, which could deter or prevent Peaks from providing services to customers, thereby harming the business.
Security breaches, loss of data, and other disruptions could compromise sensitive information related to the business or to customers or prevent access to critical information and expose the Company to liability, which could adversely affect the business and its reputation.
Failure to comply with anti-bribery, anti-corruption, and anti-money laundering laws could subject the Company to penalties and other adverse consequences.
Risks Related to Intellectual Property and Legal Proceedings
Failure to protect or enforce our intellectual property rights could harm the business and results of operations.
The Company may in the future be subject to claims that we violated the intellectual property rights of others, which are extremely costly to defend and could require us to pay significant damages and limit our ability to operate.
The Company may be subject to legal proceedings and litigation, including intellectual property disputes, which are costly to defend and could materially harm the business and results of operations.
Changes in accounting rules, assumptions, or judgments could materially and adversely affect the Company, including recent statements from the SEC regarding SPAC-related companies.
The Company faces the risk of product liability claims and may not be able to maintain or obtain insurance.
The business could be disrupted by catastrophic events and man-made problems, such as power disruptions, data security breaches, and terrorism.
Risks Related to the Company, Results of Operations, and Additional Capital Requirements
The Company has a history of net losses, anticipates increasing expenses in the future, and may not be able to achieve or maintain profitability.
The Company’s results of operations, as well as our key metrics, may fluctuate on a quarterly and annual basis, which may result in failing to meet the expectations of industry and securities analysts or its investors.
Peaks relies significantly on revenue from customers purchasing subscription-based prescription products and services and may not be successful in expanding its offerings.
The requirements of being a public company have strained and may continue to strain the Company’s resources, divert management’s attention, and may result in litigation.
The Company may require additional capital to support business growth, and this capital might not be available on acceptable terms, if at all.
If the Company’s estimates or judgments relating to its significant accounting policies prove to be incorrect, the results of operations could be adversely affected.
Adverse tax laws or regulations could be enacted, or existing laws could be applied to the Company or to customers, which could subject us to additional tax liability and related interest and penalties, increase the costs of the Company’s offerings, and adversely impact our business.
Certain U.S. state tax authorities may assert the Company has a state nexus and seek to impose state and local income taxes which could harm the results of operations.
Risks Related to Ownership of the Company Securities
Trading in our common stock on the Pink Exchange has been subject to wide fluctuations.
Our common stock is currently quoted only on the OTC Pink Marketplace, which may have an unfavorable impact on our stock price and liquidity.
The regulation of penny stocks by SEC and FINRA may discourage the tradability of our securities.
Florida law, our Articles of Incorporation, and our by-laws provides for the indemnification of our officers and directors at our expense, and correspondingly limits their liability, which may result in a major cost to us and hurt the interests of our shareholders because corporate resources may be expended for the benefit of officers and/or directors.
We do not intend to pay cash dividends on any investment in the shares of stock of our Company and any gain on an investment in our Company will need to come through an increase in our stock’s price, which may never happen.
Because our securities are subject to penny stock rules, you may have difficulty reselling your shares.
Our common stock market prices may be volatile, which substantially increases the risk that investors may not be able to sell their Securities at or above the price that was paid for the security.
Because we may issue additional shares of our common stock, investment in our company could be subject to substantial dilution.
FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our stock.
The issuance of shares to enter acquisitions may have a significant dilutive effect.

---

ITEM 1B. UNRESOLVED STAFF COMMENTS
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.

---

ITEM 2. PROPERTIES
ITEM 2. PROPERTY AND EQUIPMENT
The Company’s Subsidiary RxCompound uses a variety of pharmaceutical compounding equipment in its operations. Most of the equipment used by the Company is owned outright by the Company, but the Company does lease certain equipment. The leases for such equipment contain terms that are customary in the industries in which the Company operates. On March 31, 2024, the Company had $176,602 in property and equipment with approximately $41,250 in accumulated depreciation.

---

ITEM 3. LEGAL PROCEEDINGS
ITEM 3. LEGAL PROCEEDINGS
From time to time and during the course of business, we may become involved in various legal proceedings seeking monetary damages and other relief. The amount of the ultimate liability, if any, from such claims cannot be determined. As of the date hereof, there are no legal claims currently pending or, to our knowledge, threatened against us or any of our officers or directors in their capacity as such, or against any of our properties that, in the opinion of our management, would be likely to have a material, adverse effect on our financial position, results of operations, or cash flows.
On February 8th, 2023 the Company was made aware of a complaint against it filed in Canada by the AMF (Quebec Securities Regulator). The complaint was based on actions by previous management. The Company settled the complaint with the AMF on May 23rd, 2023 by paying a fine of $10,000 CAD ($7,452.00 USD) and agreeing not to sell any securities in Quebec.

---

ITEM 4. MINE SAFETY DISCLOSURE
ITEM 4. MINE SAFETY DISCLOSURE
Not applicable.
PART II

---

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
Our common stock is currently quoted on the OTC Pink Market under the symbol “ETST”. Our common stock has been quoted on the OTC Pink Market since October 6, 2021, under the symbol “ETST”. Because we are quoted on the OTC Pink Market, our securities may be less liquid, receive less coverage by security analysts and news media, and generate lower prices than might otherwise be obtained if they were listed on a national securities exchange.
The following table sets forth the high and low bid quotations for our common stock as reported in the Pink for the periods indicated.
Fiscal Year Ending March 31st, 2024 Low High
First Quarter - reported June 30, 2023 $ 0.022 $ 0.050
Second Quarter - reported September 30, 2023 $ 0.001 $ 0.115
Third Quarter - reported December 31, 2023 $ 0.011 $ 0.110
Fourth Quarter - reported March 31, 2024 $ 0.011 $ 0.100
Fiscal Year Ending March 31st, 2023 Low High
First Quarter - reported June 30, 2022 $ 0.023 $ 0.029
Second Quarter - reported September 30, 2022 $ 0.014 $ 0.016
Third Quarter - reported December 31, 2022 $ 0.031 $ 0.031
Fourth Quarter - reported March 31, 2023 $ 0.024 $ 0.050
HOLDERS
As of March 31, 2024, there were 215 record holders of the Company’s common stock.
DIVIDENDS
We have not paid any dividends on our common stock since our inception and do not intend to pay any dividends in the foreseeable future.
The declaration of any future cash dividends is at the discretion of our board of directors and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.
UNREGISTERED SALES OF SECURITIES
The following shares sold and issued were shares of restricted Common Stock made in reliance upon the exemptions from registration provided by Section 4(2) of the Securities Act of 1933, and/or Rule 506 of Regulation D promulgated thereunder. The investors were “accredited investors” and/or “sophisticated investors” pursuant to Section 501(a) of the Securities Act, who provided the Company with representations, warranties and information concerning their qualifications as a “sophisticated investors” and/or “accredited investors.” The Company provided and made available to the investor’s full information regarding its business and operations. There was no general solicitation in connection with the offers or sales of the restricted securities. The investors acquired the restricted common stock for their own accounts, for investment purposes, and not with a view to public resale or distribution thereof within the meaning of the Securities Act. The restricted shares so purchased cannot be sold unless pursuant to an effective registration statement by the Company, or by exemptions from registration requirements of Section 5 of the Securities Act-the existence of any such exemptions is subject to legal review and approval by the Company.
Approximately during the twelve months ended March 31, 2024, the Company issued 18,864,423 shares of its common stock for $110,000, in transactions that were exempt from registration under the Securities Act of 1933, as amended pursuant to Section 4(2) and/or Rule 506 promulgate under Regulation D. No gain or loss was recognized on the issuances. On April 5, 2023, the Company issued 5,000,000 shares to an investor at $0.005 per share for cash. On April 14, 2023, the Company issued 666,667 shares to an investor at $0.015 per share for cash. On April 27, 2023, the Company issued 5,000,000 shares to an investor at $0.005 per share for cash. On May 2, 2023, the Company issued 666,667 shares to an investor at $0.015 per share in cash. On May 4, 2023, the Company issued 2,000,000 shares to an investor at $0.005 per share for cash. On May 4, 2023, the Company issued 200,000 shares to an investor at $0.025 per share for cash. On May 24, 2023, the Company issued 5,000,000 shares to an investor at $0.005 per share for cash. On October 1, 2023, the Company issued 300,000 shares to an employee at $0.001 per share for services.
EQUITY COMPENSATION PLAN INFORMATION
The Company currently does not have an equity compensation plan in place.
COMMON STOCK
The holders of our common stock are entitled to one vote per share on all matters submitted to a vote of our stockholders. The holders of the common stock have the sole right to vote, except as otherwise provided by law, by our articles of incorporation, or in a statement by our board of directors in a Preferred Stock Designation.
In addition, such holders are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds, subject to the payment of preferential dividends or other restrictions on dividends contained in any Preferred Stock Designation, including, without limitation, the Preferred Stock Designation establishing a series of preferred stock described above. In the event of the dissolution, liquidation or winding up of Earth Science Tech, Inc., the holders of our common stock are entitled to share ratably in all assets remaining after payment of all our liabilities, subject to the preferential distribution rights granted to the holders of any series of our preferred stock in any Preferred Stock Designation, including, without limitation, the Preferred Stock Designation establishing a series of our preferred stock described above.
The holders of the common stock do not have cumulative voting rights or preemptive rights to acquire or subscribe for additional, unissued or treasury shares in accordance with the laws of the State of Florida. Accordingly, excluding any voting rights granted to any series of our preferred stock, the holders of more than 50 percent of the issued and outstanding shares of the common stock voting for the election of directors can elect all of the directors if they choose to do so, and in such event, the holders of the remaining shares of the common stock voting for the election of the directors will be unable to elect any person or persons to the board of directors. All outstanding shares of the common stock are fully paid and non-assessable.
The laws of the State of Florida provide that the affirmative vote of a majority of the holders of the outstanding shares of our common stock and any series of our preferred stock entitled to vote thereon is required to authorize any amendment to our articles of incorporation, any merger or consolidation of Earth Science Tech, Inc. with any corporation, or any liquidation or disposition of any substantial assets of Earth Science Tech, Inc.
PREFERRED STOCK
On April 21, 2022, the Company’s Board of Directors adopted articles of incorporation in the state of Nevada authorizing, without further vote or action by the stockholders, the creation, out of the unissued shares of the Company’s preferred stock, $0.001 par value Series B Preferred Stock. The Board of Directors is authorized to establish, from the authorized and unissued shares of Preferred Stock, one or more classes or series of shares, to designate each such class and series, and fix the rights and preferences of each such class of Preferred Stock; which class or series shall have such voting powers, such preferences, relative, participating, optional or other special rights, and such qualifications, limitations or restrictions as shall be stated and expressed in the resolution or resolutions providing for the issuance of such class or series of Preferred Stock as may be adopted from time to time by the Board of Directors prior to the issuance of any shares thereof. The articles of incorporation and designation authorizes the issuance of 1,000,000 shares of Preferred Stock, of which 1,000,000 shares have been designated as Series B Preferred Stock, of which 1,000,000 shares of Series B are issued and outstanding as of March 31, 2024. Each issued and outstanding share of Series B Preferred Stock shall be entitled to the number of votes equal to the result of: (i) 1.5 multiplied by the addition sum of: (A) the number of shares of Common Stock issued and outstanding at the time of such vote; and (B) the number of votes in the aggregate of any outstanding shares of any class of preferred stock of the Corporation (other than the Series B Preferred Stock), if any, at the time of such vote; with such sum divided by (ii) the total number of shares of Series B Preferred Stock issued and outstanding at the time of such vote, at each meeting of shareholders of the Corporation with respect to any and all matters presented to the shareholders of the Corporation for their action or consideration, including the election of directors. Holders of Series B Preferred Stock shall vote together with the holders of Common Shares (and any other outstanding class of preferred stock of the Corporation (other than the Series B Preferred Stock), if any.
WARRANTS
The Company does not currently have any warrants issued or outstanding.
ISSUER REPURCHASES OF EQUITY SECURITIES
During the twelve months ended March 31, 2024, the Company repurchased 5,200,000 shares of its common stock for $178,000, in private transactions through Stock Purchase Agreements with certain shareholders. On January 29, 2024, the Company repurchased 1,000,000 shares from an investor at $0.04 per share in cash. On February 16, 2024, the Company repurchased a total of 1,500,002 shares from two investors at $0.04 per share in cash. On February 22, 2024, the Company repurchased 2,000,000 shares from an investor at $0.03 per share in cash. On February 23, 2024, the Company repurchased 200,000 shares from an investor at $0.04 per share in cash. On February 26, 2024, the Company repurchased 500,000 shares from an investor at $0.02 per share in cash, these shares were cancelled.
OPTIONS
The Company has not granted any options since inception.
TRANSFER AGENT
The Company’s transfer agent is Continental Stock Transfer & Trust, Co., 1 State Street, 30th Floor, New York, NY 10004.

---

ITEM 6. SELECTED FINANCIAL DATA
ITEM 6. SELECTED FINANCIAL DATA
Not applicable to a “smaller reporting company” as defined in Item 10(f)(1) of SEC Regulation S-K.

---

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion of our financial condition and results of operations for the years ended March 31, 2024, and March 31, 2023, should be read in conjunction with our consolidated financial statements and the notes to those statements that are included elsewhere in this Annual Report on Form 10-K. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations, and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements due to several factors. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.
OVERVIEW
The Company is a holding entity set to acquire companies with its current focus in the health and wellness industry. The Company is presently in compounding pharmaceuticals and telemedicine through its wholly owned subsidiaries RxCompound, Peaks, and ESF.
RxCompound is a complete compounding pharmacy. RxCompound is currently licensed to fulfill prescriptions in 22 states: Delaware, Florida, Pennsylvania, New York, Arizona, New Jersey, Wisconsin, Minnesota, Rhode Island, Utah, Georgia, Nevada, Massachusetts, Missouri, Iowa, Maryland, Ohio, Colorado, North Carolina, Maine, Indiana and Illinois. RxCompound is in the application process to obtain licenses in the remaining states in which it is not yet licensed to fulfill prescriptions. RxCompound is in the application process to obtain licenses in the remaining states in which it is not yet licensed to fulfill prescriptions. Furthermore, RxCompound recently had its sterile compounding room approved to operate in late May 2023, to provide sterile products for injection.
Peaks is the telemedicine referral site facilitating asynchronous consultations for branded compound medications prepared at RxCompound. Peaks is currently positioned to prescribe to all 50 states utilizing third-party consultation services, but only able to fulfill prescriptions within RxCompound’s licensed states. Peaks will be able to fulfill more states as RxCompound becomes licensed in additional states.
ESF is a favored entity of ETST, effectively being a non-profit organization that was incorporated on February 11, 2019, and is structured to accept grants and donations to help those in need of assistance in paying for prescriptions.
RESULTS OF OPERATIONS
The following tables set forth summarized cost of revenue information for the year ended March 31, 2024, and for the year ended March 31, 2023, respectively.
For the Year Ending March 31,
$ Change % Change
Revenue $ 11,953,635 $ 48,537 $ 11,905,098 24,528 %
Cost of goods sold 4,125,139 26,477 4,098,662 15,480 %
Gross Profit 7,828,496 22,060 7,806,436 35,387 %
We had product sales of $11,953,635 and a gross profit of $7,828,496, representing a gross margin of 65% for the year ended March 31, 2024, compared with product sales of $48,537 and a gross profit of $22,060 representing a gross margin of 45 % in year end March 31, 2023. The revenue increase in the year ended on March 31, 2024, compared with the year ended on March 31, 2023, is primarily due to an aggressive marketing campaign and compounding products in the newly built sterile room, combined with proprietary IT that facilitates clinicians in sending prescriptions to be fulfilled and tracks shipping in real time.
Gross Margin increase is driven by the Company’s subsidiaries’ increased buying power, which provides the ability to negotiate better prices on raw active ingredient products.
For the year ended March 31, 2024, the Company had a net income of approximately $812,000 compared to a net loss from continuing operations of approximately $(365,000) for the year ended March 31, 2023.
OPERATING EXPENSES
For years ended March 31,
$ Change % Change
Labor Expense 4,358,917 97,543 4,263,399 4,371 %
Legal & Professional Fees 1,774,182 605,768 1,168,414 192 %
Bank charges 422,970 - 422,970 100 %
General and administrative
166,976 231,890 (64,914 ) (39 )%
Depreciation & amortization 149,749 17,491 125,422 717 %
Marketing 25,283 8,074 17,209 213 %
Utilities 15,368
- 15,368 100 %
Rent expense office 10,797 - 10,797 100 %
Miscellaneous 6,542 - 6,542 100 %
Insurance 5,363 - 5,363 100 %
Total operating expenses
6,936,147 $ 958,743 $ 5,972,591 622 %
Net Operating Income (Loss) $ 892,349 $ (936,683 ) $ 1,829,033 -
Other income/expenses
Other income - 618,711 (618,711 ) (100 )%
Interest Expenses 67,207 47,433 19,774 42 %
Total other income/ expenses $ 67,207 $ 571,278 $ (504,071 ) (88 )%
Net Income before taxes 825,142 (365,405 ) 1,190,547 (326 )%
Income Taxes 13,003 - - -
Net Income(Loss) $ 812,139 $ (365,405 ) $ 1,177,544 322 %
Earnings per share common and diluted 0.003 (0.003 ) 0.006 187 %
Marketing expenses totaled $25,283 for the twelve months ended March 31, 2024, an increase of $17,209 from $8,074 for the twelve months ended March 31, 2023. This increase is primarily related to the Company pushing online sales through social media marketing, and search engines.
Labor expense increased from $97,543 to $4,358,917 primarily because of the officer compensation and the need to hire additional employees.
Bank charges were $422,970, this is related to merchant fees, associated with the increase in sales.
Legal and professional fees totaled $1,774,182 for the twelve months ended March 31, 2024, an increase of $1,168,414 from $605,768 for the prior period ended March 31, 2023. The increase in legal and professional fees is due to contracting territory managers to help service our accounts, totaling $1,499,500 in consulting fees. Legal fees came down $513,386 or 93%, while other professional fees increased $196,257. This includes recruiting, auditing and accounting.
General and administrative expenses decreased from $231,890 for the year ended March 31, 2023, to $166,976 for the year ended March 31, 2024. The decrease was primarily due for the need to hire outside consulting firms to support the rapid growth of the subsidiaries as we could not hire fast enough to maintain customer satisfaction. Therefore, the company’s internal expenses decreased, while our external costs (mainly Consulting) increased significantly to $1,499,500.
We are a smaller reporting company, as defined by 17 CFR § 229.10(f)(1). We do not consider the impact of inflation and changing prices as having a material effect on our net sales and revenues and on income from our operations for the previous two years or on continuing operations going forward.
INTEREST EXPENSE
Interest expenses increased to $67,207 in the Fiscal Year Ending March 31, 2024, compared with $47,433 in Fiscal Year Ending March 31, 2023.
INCOME TAX
Estimated taxes were calculated using the 2023 federal tax rate of 21%. We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
NON-GAAP FINANCIAL MEASURES
We use Adjusted EBITDA internally to evaluate our performance and make financial and operational decisions that are presented in a manner that adjusts from their equivalent GAAP measures or that supplements the information provided by our GAAP measures. Adjusted EBITDA is defined by us as EBITDA (net income (loss) plus depreciation expense, amortization expense, interest and income tax expense, minus income tax benefit), further adjusted to exclude certain non-cash expenses and other adjustments as set forth below. We use Adjusted EBITDA because we believe it more clearly highlights trends in our business that may not otherwise be apparent when relying solely on GAAP financial measures, since Adjusted EBITDA eliminates from our results specific financial items that have less bearing on our core operating performance.
We use Adjusted EBITDA in communicating certain aspects of our results and performance, including in this Annual Report, and believe that Adjusted EBITDA, when viewed in conjunction with our GAAP results and the accompanying reconciliation, can provide investors with greater transparency and a greater understanding of factors affecting our financial condition and results of operations than GAAP measures alone. In addition, we believe the presentation of Adjusted EBITDA is useful to investors in making period-to-period comparison of results because the adjustments to GAAP are not reflective of our core business performance.
Adjusted EBITDA is not presented in accordance with, or as an alternative to, GAAP financial measures and may be different from non-GAAP measures used by other companies. We encourage investors to review the GAAP financial measures included in this Annual Report, including our consolidated financial statements, to aid in their analysis and understanding of our performance and in making comparisons.
BALANCE SHEETS & CASH FLOWS STATEMENTS
As of March 31,
ASSETS:
Current Assets
Cash $ 697,721 $ 35,756
Accounts Receivable 235,423 -
Deposits 9,352
Inventory 315,738 10,260
Total Current Assets 1,258,234 46,016
Non-Current Assets
Property and Equipment 135,352 143,213
Right of use asset, net 156,517 200,674
Goodwill 2,302,792 2,302,792
Intangible assets, net 28,441 35,276
Total non-current assets 2,623,102 2,681,955
TOTAL ASSETS $ 3,881,336 $ 2,727,971
LIABILITIES AND EQUITY:
Liabilities
Accounts Payable $ 530,724 $ 517,137
Accrued Expenses 854,719 117,193
Current portion of loans & obligations 30,592 604,767
Current portion of operating lease obligations 70,487 68,188
Total Current Liabilities 1,486,522 1,307,285
Long-Term Liabilities
Lease Liability less current maturities 84,950 96,743
SBA Loans - 204,408
Equipment Loans and Obligations non-current 60,559
Total Long-Term Liabilities 145,509 301,151
Total Liabilities 1,632,031 1,608,436
Stockholders’ Equity
Additional Paid In Capital 31,593,399 31,303,138
Common stock, par value $0.001 per share, 750,000,000 shares authorized; 309,981,819 and 282,611,083 shares issued and outstanding as of March 31, 2024, and March 31, 2023, respectively 309,982 282,612
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of March 31, 2024, and March 31, 2023, respectively 1,000 1,000
Accumulated Deficit (29,655,076 ) (30,467,215 )
Total Stockholders’ Equity 2,249,305 1,119,535
TOTAL LIABILITIES AND EQUITY $ 3,881,336 $ 2,727,971
A summary of our changes in cash flows & Statement of Financial Position for the years ended March 31, 2024, and 2023, is provided below:
The Company had $697,721 in Cash for the period ended March 31, 2024, compared with $35,756 for the same period ended March 31, 2023.
The current assets position has improved significantly, the Company has $315,738 of inventory and $235,423 in accounts receivable as of March 31, 2024, compared to $10,260 and $0 as of March 31, 2023.
The Company made an additional purchase of equipment to support its operations in the amount of $26,520 during the year ended March 31, 2024.
The Company had $530,724 in Accounts Payable for the period ended March 31, 2024, compared with $517,137 for the same period ended March 31, 2023.
Total current liabilities increased from $1,307,285 to $1,486,522, this is primarily due to executive compensation and merchant fees being accrued and settled the following month.
Long term liabilities decreased $242,012, or 62%, due to long term debt being paid off.
The Company had a Stockholders Equity of $2,249,305 for the period ended March 31, 2024, compared with $1,119,535 of Stockholders Equity for the same period ended March 31, 2023. This improvement is primarily due to Net income of approximately 812,000 and stock issuances.
STATEMENT OF CASH FLOWS
For the Years Ending March 31,
Net cash used in operating activities $ 1,206,371 $ (1,013,128 )
Net cash used in investing activities (26,520 ) -
Net cash used in financing activities (517,886 ) 1,016,568
Net increase (decrease) in cash and cash equivalents 661,965 3,440
Impact of acquisition - 5,374
Cash and cash equivalents at beginning of the period 35,756 26,942
Cash and cash equivalents at end of the period $ 697,721 $ 35,756
CASH FLOWS FROM OPERATING ACTIVITIES
The Company’s net cash from operating activities was $1,206,371 for Fiscal Year Ending March 31, 2024, and $(1,013,128) Fiscal Year Ending March 31, 2023.
CASH FLOWS FROM INVESTING ACTIVITIES
During the Fiscal Year ending March 31, 2024, and March 31, 2023, the Company used $(26,520) in investing activities and $0, respectively.
CASH FLOWS FROM FINANCING ACTIVITIES
Net Cash used in financial activities was $(517,886).
During the Fiscal Year ending March 31, 2024, the Company bought 5,200,000 shares of common stock for an average price of $0.034 per share, or an aggregate amount of $178,000. The shares were cancelled.
Promissory note in the amount of $250,000, and SBA Loans of approximately $204,000 plus interest were paid off during the Fiscal Year Ending March 31, 2024.
FUTURE FINANCING
The company does not anticipate needing any future financing, unless it undertakes an acquisition.
STOCK BASED COMPENSATION
On August 1, 2023, the Company’s subsidiary, RxCompound, entered into an agreement with its chief pharmacist, Shibu John. Under the terms of the employment agreement Mr. John was issued 300,000 shares of Company’s restricted common stock at par value as additional compensation.
RECENT ACCOUNTING PRONOUNCEMENTS
The company has assessed the impact of recent pronouncements in the preparation of Consolidated Financial Statements and their impact has been disclosed in note 2.
OFF- BALANCE SHEET ARRANGEMENTS
None.

---

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK
Not applicable to a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K.

---

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The financial statements required by this item are set forth at the pages indicated in Part IV, Item 15(a)(1) of this Annual Report.
EARTH SCIENCE TECH, INC. AND SUBSIDIARIES
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of March 31, 2024, and March 31, 2023
Consolidated Statements of Operations for the Years Ended March 31, 2024, and March 31, 2023
Consolidated Statements of Changes in Shareholders’ Equity for the Years ended March 31, 2024, and 2023
Consolidated Statements of Cash Flows for the Years Ended March 31, 2024, and March 31, 2023
Notes for the Consolidated Financial Statements
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and
Stockholders’ of Earth Science Tech, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheet of Earth Science Tech, Inc. and its Subsidiaries (the Company) as of March 31, 2024, and the related consolidated statements of operations, stockholders’ equity, and cash flows for the year ended March 31, 2024, and the related consolidated notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2024 and the results of its operations and its cash flows for year ended March 31, 2024, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
We did not identify any critical audit matters that need to be communicated.
Assurance Dimensions
We have served as the Company’s auditor since 2024.
Margate, Florida
June 28, 2024
ASSURANCE DIMENSIONS, LLC
also d/b/a McNAMARA and ASSOCIATES, LLC
TAMPA BAY: 4920 W Cypress Street, Suite 102 | Tampa, FL 33607 | Office: 813.443.5048 | Fax: 813.443.5053
JACKSONVILLE: 4720 Salisbury Road, Suite 223 | Jacksonville, FL 32256 | Office: 888.410.2323 | Fax: 813.443.5053
ORLANDO: 1800 Pembrook Drive, Suite 300 | Orlando, FL 32810 | Office: 888.410.2323 | Fax: 813.443.5053
SOUTH FLORIDA: 2000 Banks Road, Suite 218 | Margate, FL 33063 | Office: 754.800.3400 | Fax: 813.443.5053
www.assurancedimensions.com
“Assurance Dimensions” is the brand name under which Assurance Dimensions, LLC including its subsidiary McNamara and Associates, LLC (referred together as “AD LLC”) and AD Advisors, LLC (“AD Advisors”), provide professional services. AD LLC and AD Advisors practice as an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable laws, regulations, and professional standards. AD LLC is a licensed independent CPA firm that provides attest services to its clients, and AD Advisors provide tax and business consulting services to their clients. AD Advisors, and its subsidiary entities are not licensed CPA firms.
Report of Independent Registered Public Accounting Firm
To the shareholders and Board of Directors of Earth Science Tech, Inc.
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated financial statements of Earth Science Tech, Inc. as of March 31, 2023, the related statements of operations, stockholders’ equity (deficit), and cash flows for the year then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s Goodwill and our report dated June 19, 2023, except for the effect of the material weaknesses described in the third paragraph of that report, as to which the date is February 19, 2024, expressed an adverse opinion thereon.
The Company’s Ability to Continue as a Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered negative cash flows and has a significant accumulated deficit. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
Critical Audit Matters
Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.
We determined that there are no critical audit matters.
R. Bolko, CPA P.A. (PCAOB ID 6554)
We have served as the Company’s auditor since 2022.
Boca Raton, FL
June 19, 2023, except the restatement disclosed in Notes of the consolidated financial statements, as which the date is February 19, 2024.
EARTH SCIENCE TECH, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AS OF MARCH 31, 2024, AND 2023
As of March 31,
ASSETS
Current Assets
Cash $ 697,721 $ 35,756
Accounts Receivable 235,423 -
Deposits 9,352 -
Inventory 315,738 10,260
Total Current Assets 1,258,234 46,016
Non-Current Assets
Property and Equipment, net 135,352 143,213
Right of use asset, net 156,517 200,674
Goodwill 2,302,792 2,302,792
Intangible assets, net 28,441 35,276
TOTAL ASSETS $ 3,881,336 $ 2,727,971
LIABILITIES AND EQUITY
Liabilities
Accounts Payable $ 530,724 $ 517,137
Accrued Expenses and other payables 854,719 117,193
Current portion of loans & obligations 30,592 604,767
Current portion of operating lease obligations 70,487 68,188
Total Current Liabilities 1,486,522 1,307,285
Long-Term Liabilities
Lease Liability less current maturities 84,950 96,743
SBA Loans - 204,408
Equipment Loans and Obligations non-current 60,559 -
Total Liabilities 1,632,031 1,608,436
Commitment and Contingencies (Note 10)
Stockholders’ Equity
Additional Paid In Capital 31,593,399 31,303,138
Common stock, par value $0.001 per share, 350,000,000 shares authorized; 309,981,819 and 282,611,083 shares issued and outstanding as of March 31, 2024, and March 31, 2023, respectively 309,982 282,612
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of March 31, 2024, and March 31, 2023, respectively 1,000 1,000
Accumulated Deficit (29,655,076 ) (30,467,215 )
Stockholders’ Equity 2,249,305 1,119,535
TOTAL LIABILITIES AND EQUITY $ 3,881,336 $ 2,727,971
EARTH SCIENCE TECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR YEARS ENDED MARCH 31, 2024, AND 2023
Revenue $ 11,953,635 $ 48,537
Cost of Goods Sold (exclusive of depreciation shown separately below) 4,125,139 26,477
Gross Profit 7,828,496 22,060
Expenses
Labor Expense 4,358,917 95,520
Legal & Professional Fees 1,774,182 605,768
Bank Charges
422,970 -
General and Administrative Expenses
166,976 231,890
Depreciation and amortization
149,749 17,491
Marketing
25,283 8,074
Utilities
15,368 -
Rent expense
10,797 -
Miscellaneous
6,542 -
Insurance 5,363 -
Total Expenses $ 6,936,147 $ 958,743
Net Operating Income/(Loss) 892,349 (936,683 )
Other income/expenses
Other income - 618,711
Interest Expenses (67,207 ) (47,433 )
Total other income/ expenses (67,207 ) 571,278
Net Income/(loss) before taxes 825,142 (365,405 )
Income Taxes 13,003 -
Net Income/Loss $ 812,139 $ (365,405 )
Profit/(Loss) per common share-Basic and Diluted $ 0.003 $ (0.003 )
Weight average number of shares outstanding 309,687,386
145,867,024
EARTH SCIENCE TECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY
FOR YEARS ENDED MARCH 31, 2024, AND 2023
Common Stock Preferred Stock Additional paid in Accumulated
deficit
Description Shares Amount Shares Amount Capital (Restated) Total
Balance at March 31, 2022 53,851,966 53,853 - - 28,264,452 (30,123,718 ) $ (1,805,413 )
Common stock issued for cash 87,246,677 87,247 - - 476,953 - $ 564,200
Common stock issued for operating claims 1,700,000 1,700 - - - - $ 1,700
Common stock issued for officer’s compensation 3,500,000 3,500 - - - - 3,500
Preferred stock B issued for officer’s compensation
1,000,000 1,000 - - 1,000
Common stock issued for debt settlement 85,612,440 85,612 - - 736,533 - 822,145
Common stock issued for acquisition of RX and Peaks 50,700,000 50,700 - - 1,825,200 - $ 1,875,900
Net Profit/(Loss)
(365,405 (365,405 )
Balance at March 31, 2023 282,611,083 $ 282,612 1,000,000 $ 1,000 $ 31,303,138 $ (30,467,215 ) $ 1,119,535
Shares
Amount
Shares
Amount
APIC
Earnings Total
Common Stock Preferred Stock
Accumulated
Shares
Amount
Shares
Amount
APIC
Deficit Total
Balance at March 31, 2023 282,611,083 $ 282,612 1,000,000 $ 1,000 $ 31,303,138 $ (30,467,215 ) $ 1,119,535
Balance 282,611,083 $ 282,612 1,000,000 $ 1,000 $ 31,303,138 $ (30,467,215 ) $ 1,119,535
Common stock issued for cash 18,864,423 18,864 - - 91,467 - 110,331
Common stock buyback (5,200,000 ) (5,200 )
(172,800 )
(178,000 )
Stock -based compensation 300,000 - - - -
Common stock issued for conversion of debt 13,406,313 13,406
371,594
385,000
Net Income
-
- - 812,139 812,139
Balance at March 31, 2024 309,981,819 $ 309,982 1,000,000 $ 1,000 $ 31,593,399 $ (29,655,076 ) $ 2,249,305
Balance 309,981,819 $ 309,982 1,000,000 $ 1,000 $ 31,593,399 $ (29,655,076 ) $ 2,249,305
EARTH SCIENCE TECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR YEARS ENDED MARCH 31, 2024, AND 2023
Cash flows from operating activities:
Net Income (Loss) $ 812,139 $ (365,405 )
Adjustments to reconcile net income to net cash provided (used) by operating activities:
Stock-based compensation 4,500
Gain on payable settlement - (618,711 )
Depreciation and amortization 149,749 17,491
Changes in operating assets and liabilities:
Accounts Receivable (235,423 ) -
Deposits (9,352 ) -
Inventory (305,478 ) -
Lease liability, net
(73,870 ) -
Accrued settlement - 235,947
Accounts payable and accrued expenses 868,306 (286,949 )
Net cash provided (used) by operating activities 1,206,241 (1,013,128 )
Cash flows from investing activities:
Purchases of property and equipment (26,520 ) -
Net cash used in investing activities (26,520 ) -
Cash flows from financing activities:
Net proceeds from issuance of common stock 110,331 564,200
Repurchase of common stock (178,000 ) -
Payments on debt obligations (450,217 ) (97,612 )
Proceeds from loans and notes - 549,980
Net Cash used in Financing Activities (517,886 ) 1,016,568
Net increase (decrease) in cash and cash equivalents 661,965 3,440
Impact of acquisition - 5,374
Cash and cash equivalents at beginning of the period 35,756 26,942
Cash and cash equivalents at end of the period $ 697,721 $ 35,756
Supplemental Disclosure of Cash Flow Information
Cash paid for interest $ 67,207 $ 47,433
Cash paid for income taxes $ - $ -
$ $
Non-Cash Transactions $ $
Common stock issued for acquisition of subsidiaries $ - $ 1,875,900
Common stock issued for debt settlement $ - $ 822,145
Common stock issued for operating claims $ - $ 1,700
Common stock issued for officer’s compensation $ - $ 3,500
Preferred B stock issued for officer’s compensation $ - $ 1,000
Common stock issued on conversion of notes payable $
385,000 $ -
N ote 1 - Organization and Nature of Operations
Earth Science Tech, Inc. (“ETST” or the “Company”) was incorporated under the laws of the State of Nevada on April 23, 2010. The Company subsequently changed its domicile to the State of Florida on June 27, 2022. As of November 8, 2022, the Company is a holding entity set to acquire companies with its current focus in the health and wellness industry. The Company is presently in compounding pharmaceuticals and telemedicine through its wholly owned subsidiaries RxCompoundStore.com, LLC. (“RxCompound”), Peaks Curative, LLC. (“Peaks”), and Earth Science Foundation, Inc. (“ESF”).
RxCompound is a complete compounding pharmacy. RxCompound is currently licensed to fulfill prescriptions in 22 states: Delaware, Florida, Pennsylvania, New York, Arizona, New Jersey, Wisconsin, Minnesota, Rhode Island, Utah, Georgia, Nevada, Massachusetts, Missouri, Iowa, Maryland, Ohio, Colorado, North Carolina, Maine, Indiana and Illinois. RxCompound is in the application process to obtain licenses in the remaining states in which it is not yet licensed to fulfill prescriptions.
Peaks is a telemedicine referral site focused on overall health and wellness for men and women. Peaks’ orders are exclusively fulfilled by RxCompound. Patients who order Peaks via monthly subscription receive their refills automatically. The company intends to expand offerings to include over the counter (“OTC”) (non-prescription) products such as supplements and topicals. .
ESF is a favored entity of ETST, effectively being a non-profit organization that was incorporated on February 11, 2019, and is structured to accept grants and donations to help those in need of assistance in paying for prescriptions.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation
The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).
Principles of consolidation
The accompanying consolidated financial statements include all the accounts of the Company and its wholly owned subsidiaries RxCompound, Peaks and ESF.
Use of estimates and assumptions
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas requiring significant estimates are impairment of goodwill, provision for taxation, useful life of depreciable assets, useful life of intangible assets, contingencies, and going concern assessment. The estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from those estimates.
Impairment of Long-Lived Assets
The Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable through the estimated undiscounted cash flows expected to result from the use and eventual disposition of the assets. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value. As of and for the years ended March 31, 2024 and 2023 no such impairment was needed.
Cash and cash equivalents.
Cash and cash equivalents include all highly liquid debt instruments with original maturities of twelve months or less, which secure any corporate obligations. As of March 31, 2024, and March 31, 2023, the Company held a cash balance of $697,721 and $35,756 respectively As of March 31, 2024, the organization’s balances exceeded federally insured limits by approximately $266,090.
Accounts Receivable.
Upon adoption of ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the presentation and disclosure of receivables will change significantly. ASU 2016-13 introduces a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The ASU also provides updated guidance regarding the impairment of available-for-sale debt securities and includes additional disclosure requirements.
Additionally, ASU 2022-02 eliminates the accounting guidance for TDRs in ASC 310-40, Receivables - Troubled Debt Restructurings by Creditors, but introduces new disclosure requirements for loan modifications with borrowers experiencing financial difficulty. The elimination of TDRs can only be applied by entities that have adopted the CECL model introduced by ASU 2016-13.
The Company has adopted the new standard ASC-326- CECL to account for current credit losses, the Company has analyzed its accounts receivable, based on historical and customer experience, economic trends, and future estimates. Accounts receivables are recorded for pharmaceuticals picked up or shipped as of March 31, 2024, it is expected to be collected within twelve months in its entirety, no reserve was necessary.
SCHEDULE OF ACCOUNTS RECEIVABLE
As of March 31,
Accounts Receivable $ 235,423 $ -
Revenue recognition
The Company has implemented ASC 606, Revenue from Contracts with Customers for revenue recognition by incorporating the necessary changes in systems and processes. These changes included the development of new policies based on the five-step model provided in the new revenue standard, ongoing contract review requirements, and gathering of information provided for disclosures. Revenue is recognized at this point in time.
The Company recognizes revenue from product sales or services rendered when control of the promised goods is transferred to our customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods and services. To achieve this core principle, we apply the following five steps: identify the contract with the client, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to performance obligations in the contract and recognize revenue when or as the Company satisfies a performance obligation, such as shipping with a third party, or upon pick up of the pharmaceuticals.
Disaggregated Revenue
The Company disaggregates revenue from contracts with customers by category - core and non-core, as it believes it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
The Company’s disaggregated revenue by category is as follows:
SCHEDULE OF DISAGGREGATED REVENUE
For the Years Ending March 31,
Core:
Sale of Pharmaceutical products - RxCompound $ 11,924,804 $ 44,099
Total core revenue, net $ 11,924,804 $ 44,099
Non-Core: - -
Services - Peaks $ 28,831 $ 4,438
Total revenue, net $ 11,953,635 $ 48,537
The Company currently has 3 large customers, each representing 14 %, 9% and 9% of revenue.
SCHEDULE OF REVENUE BY MAJOR CUSTOMERS
For the Years Ending March 31,
Accounts Receivables $ 235,423 $ -
Inventory
The Company has its inventories stated at a lower cost (on first in, first out (FIFO) method) or market value basis. A reserve is established if necessary to reduce excess or obsolete inventories to their realizable value. The stated cost consists of finished products. Reserves, if necessary, are recorded to reduce inventory to market value based on assumptions about consumer demand, current inventory levels and product life cycles for the various inventory items. These assumptions are evaluated annually and are based on the Company’s business plan and on feedback from customers and the product development team. As of March 31, 2024, and March 31, 2023, the inventory reserves were not material.
The Company has three main suppliers, each accounting 32%, 13% and 6% of the company’s vendor purchases.
SCHEDULE OF INVENTORY
As of March 31,
Raw materials $ 266,776
Finished goods 48,962 10,260
Inventory $ 315,738 $ 10,260
Cost of Goods Sold
Components of cost of goods sold include product costs, consumables, shipping costs to customers and any inventory adjustments.
Shipping and Handling
Costs incurred by the Company for shipping and handling are included in costs of goods sold.
Related Parties
The Company pays the employee compensation for Giorgio R. Saumat and Mario Tabraue to their respective, solely owned LLCs, Point96 Consulting, LLC and Tabraue Consulting, LLC.
The Company follows ASC 850-10, Related Parties, for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20, the related parties include: (a) affiliates of the Company (“Affiliate” means, with respect to any specified person, any other person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such person, as such terms are used in and construed under Rule 405 under the Securities Act); (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.
Income taxes
The Company accounts for income taxes under ASC 740, Income Taxes. Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Net income per common share
The Company follows ASC 260 to account for earnings per share. Basic earnings per common share calculations are determined by dividing net results from operations by the weighted average number of shares of common stock outstanding during the year. Diluted loss per common share calculation is determined by dividing net results from operations by the weighted average number of common shares and diluted common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. For the years ended March 31, 2024 and 2023, the Company did not have any antidilutive equity instruments.
Goodwill
Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a purchase business combination. Goodwill is reviewed for impairment on an annual basis, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may be impaired. In conducting its annual impairment test, the Company first reviews qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If factors indicate that the fair value of the reporting unit is less than its carrying amount, the Company performs a quantitative assessment, and the fair value of the reporting unit is determined by analyzing the expected present value of future cash flows. If the carrying value of the reporting unit continues to exceed its fair value, the fair value of the reporting unit’s goodwill is calculated and an impairment loss equal to the excess is recorded.
Stock Based Compensation
The Company applies the fair value method of ASC 718, Compensation-Stock Compensation, in accounting for its stock-based compensation. These standards state that compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period, if any. The Company uses the Black-Scholes option pricing model to determine the fair value of its stock, stock option and warrant issuance. The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price, as well as assumptions regarding a few complex and subjective variables. These variables include the Company’s expected stock price, volatility over the term of the awards, actual employee exercise behaviors, risk-free interest rate and expected dividends. The company issued common stock for services provided by officers and others, during the year ended March 31, 2024. However, no stock-based commitments were outstanding as of March 31, 2024, and 2023.
Cash flows reporting
The Company follows ASC 230 to report cash flows. This standard classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by this standard to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments. The Company reports separately information about investing and financing activities not resulting in cash receipts or payments in the period pursuant to this standard.
Fair Value
FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories:
Level 1 - Quoted market prices for identical assets or liabilities in active markets or observable inputs,
Level 2 - Significant other observable inputs that can be corroborated by observable market data; and
Level 3 - Significant unobservable inputs that cannot be corroborated by observable market data.
The carrying amounts of cash, accounts payable and other liabilities, accrued expenses and settlement payable approximate fair value because of the short-term nature of these items.
The fair value of the Company’s debt approximated the carrying value of the Company’s debt as of March 31, 2024, and as of March 31, 2023. Factors that the Company considered when estimating the fair value of its debt included market conditions, liquidity levels in the private placement market, variability in pricing from multiple lenders and terms of debt.
Property and equipment
Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. During the year ended March 31, 2024, RxCompound added various equipment for its hazardous room, to compound hormonal creams. Depreciation on property and equipment is charged using a straight-line method over the estimated useful life of 5 years.
Recently issued accounting pronouncements
We have considered the impact of the following pronouncements:
The Company has adopted the new standard ASC-326- CECL to account for current credit losses, the Company has analyzed this pronouncement noting no material impact upon adoption.
The FASB recently issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, which requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities for fiscal years beginning after December 15, 2021, with early adoption permitted (for an “emerging growth company,” beginning after December 15, 2023). The Company has assessed the impact this standard will have on the Company’s consolidated financial statements. No material adjustments will be required.
Intangible assets
Intangible assets consist of Peaks telemedicine platform, and the Holding Company’s web domains. Intangible assets with finite lives are amortized over the estimated useful life of five years.
NOTE 3- INVENTORY
The Company has its inventories stated at a lower cost (on first in, first out (FIFO) method) or market value basis. A reserve is established if necessary to reduce excess or obsolete inventories to their realizable value. The stated cost consists of finished products. Reserves, if necessary, are recorded to reduce inventory to market value based on assumptions about consumer demand, current inventory levels and product life cycles for the various inventory items. These assumptions are evaluated annually and are based on the Company’s business plan and on feedback from customers and the product development team. As of March 31, 2024, and March 31, 2023, the inventory reserves were not material.
SCHEDULE OF INVENTORIES
As of March 31,
Raw materials $ 266,776 $ -
Finished goods 48,962 10,260
Inventory $ 315,738 $ 10,260
NOTE 4 - PROPERTY AND EQUIPMENT, NET
SCHEDULE OF PROPERTY AND EQUIPMENT
As of March 31,
Equipment - cost $ 176,602 $ 150,082
Less: Accumulated depreciation (41,250 ) (6,869 )
Property and Equipment, Net $ 135,352 $ 143,213
Depreciation expenses for the years ended March 31, 2024, and March 31, 2023, were $34,381 and $6,869, respectively.
NOTE 5- LEASES
The Company treats a contract as a lease when the contract conveys the right to use a physically distinct asset for a period in exchange for consideration, or the Company directs the use of the asset and obtains substantially all the economic benefits of the asset. These leases are recorded as right-of-use (“ROU”) assets and lease obligation liabilities for leases with terms greater than 12 months. ROU assets represent the Company’s right to use an underlying asset for the entirety of the lease term. Lease liabilities represent the Company’s obligation to make payments over the life of the lease. A ROU asset and a lease liability are recognized at commencement of the lease based on the present value of the lease payments over the life of the lease. Initial direct costs are included as part of the ROU asset upon commencement of the lease. Since the interest rate implicit in a lease is generally not readily determinable for the operating leases, the Company uses an incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate represents the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar lease term to obtain an asset of similar value.
The Company reviews the impairment of ROU assets consistent with the approach applied for the Company’s other long-lived assets. The Company reviews the recoverability of long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company elected the practical expedient to exclude short-term leases (leases with original terms of 12 months or less) from ROU asset and lease liability accounts.
Supplemental balance sheet information related to leases were as follows:
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES
As of March 31,
Assets
Right of use asset, net $ 156,517 $ 200,674
Operating lease liabilities
Current 70,487 68,188
Non-current 84,950 96,743
Total Lease Liabilities $ 155,797 $ 164,931
The components of lease cost were as follows:
SCHEDULE OF LEASE COST
For the Years Ending March 31,
Depreciation $ 108,533 $ 15,436
Interest on lease obligation 5,595 2,935
Total lease cost $ 114,128 $ 18,372
Lease term and discount rate were as follows:
SCHEDULE LEASE TERM AND DISCOUNT RATE
For the Years Ending March 31,
Weighted average remaining lease term - Operating leases 2.25 years 3.25 years
Weighted average discount rate - Operating leases 3 % 3 %
Disclosure on maturity of undiscounted minimum lease payments (per year)
SCHEDULE OF MATURITY UNDISCOUNTED MINIMUM LEASE PAYMENTS
Year ended March 31 Operating Leases
$ 74,001
74,001
12,334
Total 160,336
Less interest 4,539
Present value of lease payment $ 155,797
NOTE 6 - INTANGIBLE ASSETS
Intangible assets, consisted of the following:
SCHEDULE OF INTANGIBLE ASSETS
As of March 31,
Telemedicine Platform $ 17,806 $ 17,806
Web Domain $ 19,323 $ 19,323
Accumulated Amortization $ (8,688 ) $ (1,853 )
Net Balance $ 28,441 $ 35,276
Amortization expense $ 6,835 1,853
NOTE 7- GOODWILL
Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in the business combinations as well as the Goodwill recorded on the acquired subsidiary of RxCompoundStore.com, LLC. On November 08, 2022, the Company acquired 100% of the outstanding equity shares of RxCompoundStore.com, LLC and Peaks Curative, LLC against the share exchange consideration and recognized Goodwill.
SCHEDULE OF GOODWILL
As of March 31,
RxCompound and Peaks $ 2,302,792 $ 2,302,792
Total $ 2,302,792 $ 2,302,792
The Company conducted an impairment test as of March 31, 2024, and March 31, 2023, and no indication of impairment was identified.
NOTE 8- ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable and accrued expenses consisted of the following:
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES
As of March 31,
Accounts Payable $ 530,724 $ 517,137
Accrued Expenses (A) $ 854,719 $ 117,193
(A) Accrued Expenses
As of March 31, 2024, accrued expenses included executive compensation of approximately $650,000, and merchant fees of approximately $68,000.
NOTE 9 - DEBT
Loans Notes Payable consisted of the following
SCHEDULE OF NOTES AND LOANS PAYABLE
Name Total Current Non-Current
As of March 31, 2024
Equipment Finance $ 91,151 $ 30,592 $ 60,559
As of March 31, 2023
SBA Loan $ 209,175 $ 4,767 $ 204,408
Revolving Promissory Note $ 250,000 $ 250,000 -
Convertible Promissory Note $ 350,000 $ 350,000 -
Loans Notes Payable $ 809,175 $ 604,767 $ 204,408
Revolving Promissory Note in the amount of $250,000 and SBA Loan in the amount of $209,175 were paid off during the year
Convertible promissory Notes in the amount of $200,000 and $150,000 and corresponding accrued interest of $35,000 were converted to common stock as follows:
June 5, 2023- Total amount of principal and interest converted $165,000 at an applicable average closing price of $0.0378, discounted after 25% reduction from average $0.0283, the number of shares to be issued pursuant to the conversion of the note 5,820,106.
June 12, 2023- Total amount of principal and interest converted $220,000 at an applicable average 10 closing price of $0.04, discounted after 25% reduction from average $0.029, the number of common stock issued pursuant to the conversion 7,586,207.
No additional debt was incurred during the fiscal year ending March 31, 2024
For the years ending March 31, 2024 and 2023, total interest expense for the year was $67,207 and $47,433 respectively.
NOTE 10 - ACQUISITION AND RELATED TRANSACTIONS
On or about November 3, 2021 the Company entered into an agreement for the purchase of RxCompoundStore.com, LLC and Peaks Curative, LLC through the purchase of 100% of the outstanding equity securities of both entities. The agreement was amended on November 8, 2022, to incorporate share exchange consideration only. The Company’s acquisition of RxCompound was consummated on November 8, 2022, along with Peaks; however, RxCompound completed its PCAOB audit on February 3, 2023, which was considered as its acquisition date.
Subsidiaries operating results were consolidated according to the above acquisition dates. Shortly after entering into the purchase agreement with RxCompoundstore.com and Peaks Curative, the Company shifted from formulating and selling CBD products to formulating pharmaceutical products and topicals for sale through its accounts and the telemedicine platform of Peaks Curative. Consequently, in the year ended March 31, 2023, no revenue was recognized by the Holding Company but generated revenue of $48,537 through RxCompound and Peaks.
As consideration for the acquisition, an aggregate of 50,700,000 shares of the Company’s Common Stock of the Earth Science Tech, Inc were issued to the shareholders of subsidiaries in following proportion:
SCHEDULE OF AN AGGREGATE SHARES OF THE COMMON STOCK
Shareholder of Subsidiaries Shares of
Common Stock
Mario G. Tabraue 9,750,000
Jose Rodriguez 19,750,000
Mario Portela 17,000,000
Adrian Raventons 2,000,000
Frank Garcia 2,000,000
Sam Garcia 200,000
Total 50,700,000
NOTE 11 - COMMITMENTS AND CONTINGENCIES
Commitments and contingencies
The Company follows ASC 450 to account for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. This may result in contingent liabilities that are required to be accrued or disclosed in the financial statements. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.
Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s consolidated financial position, results of operations, or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.
Legal Matters:
From time to time and in the course of business, we may become involved in various legal proceedings seeking monetary damages and other relief. The amount of the ultimate liability, if any, from such claims cannot be determined. As of the date hereof, there are no legal claims currently pending or, to our knowledge, threatened against us or any of our officers or directors in their capacity as such or against any of our properties that, in the opinion of our management, would be likely to have a material adverse effect on our financial position, results of operations or cash flows.
On September 19, 2023, one of the Company’s subsidiaries, RxCompoundStore.Com, LLC was sued in Federal court by Eli Lilly. RxCompoundStore.Com, LLC was able to successfully defend itself and on April 10, 2024, the case was dismissed with prejudice.
On February 8th, 2023 the Company was made aware of a complaint against it filed in Canada by the AMF (Quebec Securities Regulator). The complaint was based on actions by previous management. The company settled the complaint with the AMF on May 23rd, 2023 by paying a fine of $10,000 CAD ($7,452.00 USD) and agreeing not to sell any securities in Quebec
Employment and Consulting Agreements:
On September 29, 2023, the Company adopted a new officer compensatory plan arrangement superseding its prior arrangement. For the officers Giorgio R. Saumat, the Company’s CEO and Chairman of the Board shall be compensated twenty one percent of the Company’s monthly revenue. For the officer Mario G. Tabraue, the Company’s President and Director of the Board shall receive ten and a half percent of the monthly revenue. Commencing on October 1, 2023, within a twelve-month term, both Officers shall be paid on the first of the month, based on the preceding month’s revenue as long as the Company increases its cash position quarter over quarter. In the event that the Company does not increase its cash position, the arrangement must be renegotiated and there will be no payment at the beginning of the new quarter. Moreover, both officers have agreed to waive all rights to back pay and compensation for the work done in the Company prior to September 30, 2023. As of March 31, 2024 a total of $652,220 was accrued for executive compensation for Giorgio R. Saumat and Mario G. Tabraue. Moreover Giorgio R. Saumat, Mario G. Tabraue and Jeff P.H. Cazeau will be compensated two thousand dollars per board of Directors meeting attended for all services rendered.
On November 7, 2023, a voting majority entitled by action without meeting of the Company’s shareholders elected Yovan Sanchez as the Company’s Director of the Board. Mr. Sanchez will be compensated two thousand dollars per board of Directors meeting attended for all services rendered.
On November 8, 2023, a voting majority entitled by action without meeting of the Company’s shareholders elected Emiliano Curia as the Company’s Independent Director of the Board. Curia will be compensated two thousand dollars per board of Directors meeting attended for all services rendered.
On March 4, 2024, the Board of Directors of the Company hired Ernesto L. Flores as the Company’s CFO, succeeding Gabrielle Schuster. Mr. Flores will receive an annual base salary of one hundred sixty thousand dollars, paid biweekly. Additionally, Mr. Flores will receive bonuses upon completing agreed-upon milestones and may be eligible for a year-end discretionary bonus determined by the Chief Executive Officer of the Company.
NOTE 12 - EQUITY
Common stock:
The Company has authorized 350,000,000 shares of $.001 par value common stock. As of March 31, 2024, and March 31, 2023, the Company had 309,981,819 and 282,611,083 shares, respectively, of common stock issued and outstanding.
During the year ended March 31, 2024, the Company issued 18,864,423 shares of common stock for approximately $110,000.
In June 2023, the Company issued a total of 13,406,313 shares for the conversion of two convertible notes by an investor, for $385,000.
During the year ended March 31, 2024, the Company repurchased 5,200,000 shares of common stock for cash consideration of $178,000, the shares were cancelled.
On November 28, 2023, the Company amended its Articles Incorporation (the “Amendment’) in the State of Florida to reduce its Authorized Shares of Common Stock from 750,000,000 shares to 350,000,000 shares. The Amendment was passed through a voting majority Shareholder Written Consent and a Corporate Resolution. The Amendment was stamped and uploaded by the State of Florida on January 8, 2024
On August, 2023 the company issued 300,000 shares of common stock as compensation to the Chief Pharmacist Shibu John, for total of $300.
NOTE 13 - RELATED PARTY TRANSACTIONS
Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial and operating decisions. Transactions with related parties have been disclosed in debt, acquisition and officer’s compensation notes.
June 5, 2023- Total amount of principal and interest converted $165,000 at an applicable avg closing price of $0.0378, discounted after 25% reduction from avg $0.0283, the number of shares to be issued pursuant to the conversion of the note 5,820,106.
June 12, 2023- Total amount of principal and interest converted $220,000 at an applicable avg 10 closing prices of $0.04, discounted after 25% reduction from average $0.029, the number of common stock issued pursuant to the conversion 7,586,207.
Officer compensation totaling $3,611,594 was incurred during the year, paid to Point 96 Consultant owned by Giorgio R. Saumat and Tabraue Consulting, owned by Mario Tabraue.
Additionally, the Company reimbursed Point 96 Consultant for marketing and SG&A in the amount of $428,000.
NOTE 14 - INCOME TAXES
The Company accounts for income taxes under ASC 740, Income Taxes. Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
The components of deferred tax assets and liabilities at March 31, 2024 and 2023 are approximately as follows:
SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS AND LIABILITIES
Year ending March, 31
Deferred Tax assets:
Net Operating loss carry forwards $ 1,664,522 $ 1,803,411
Valuation Allowance $ (1,491,173 ) $ (1,803,411 )
Book to tax depreciation difference- Liability $ (173,349 ) -
Net deferred tax asset $ -
The income tax provision differs from the amount of income tax determined by applying the U.S. federal and state income tax rates to pretax (income) loss from operations for the years ended March 31, 2024 and 2023 due to the following:
SCHEDULE OF PRETAX (INCOME) LOSS FROM OPERATIONS
Tax Expense $ 151,683 -
Valuation Allowance $ (138,680 ) -
Net tax expense $ 13,003 -
Income tax expense rates for the years ended March 31, 2024 and 2023 is as follows:
SCHEDULE OF INCOME TAX EXPENSE RATES
Federal 21.0 % 21 %
State 5.5 % 5.5 %
Federal and State 26.5 % 26.5 %
Valuation (24.9 )% (26.5 )%
Net effective tax rate 1.6 % -
ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. This first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely to be realized upon ultimate settlement. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments, and which may not accurately anticipate actual outcomes.
The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of March 31, 2024, the Company has not recorded any unrecognized tax benefits.
Interest and penalties related to liabilities for uncertain tax positions will be charged to interest and operating expenses, respectively. The Company has net operating loss carryforwards (NOL) for income tax purposes of approximately $4,129,059 pre 2018, and $3,797,234 post 2018. This loss is allowed to be offset against future income. The tax benefits relating to all timing differences have been partially used for in the valuation allowance account due to profit generated during fiscal year ending March 31, 2024.
Internal Revenue Code Section 382 (“Section 382”) imposes limitations on the availability of a company’s net operating losses after certain ownership changes occur. Section 382 limitation is based upon certain conclusions pertaining to the dates of ownership changes and the value of the Company on the dates of the ownership changes. It was determined that an ownership change occurred in October 2013 and March 2014. The amount of the Company’s net operating losses incurred prior to the ownership changes is limited based on the value of the Company on the date of the ownership change. Management has not determined the amount of net operating losses generated prior to the ownership change available to offset taxable income after the ownership change.

---

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS

---

ITEM 9A. CONTROLS AND PROCEDURES
ITEM 9A. CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS & PROCEDURES
Disclosure Controls and Procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired control objectives. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.
The Company’s management, including the Chief Executive Officer and Chief Financial Officer have reviewed and evaluated the effectiveness of the Company’s design and operations of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) as of the end of the period covered by this annual Report on Form 10-K/A. Based on that review and evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this Annual report, the Company’s disclosure controls and procedures were ineffective as of March 31, 2024.
Management’s Annual Report on Internal Control Over Financial Reporting
Our disclosure controls and procedures contain components of our internal controls over financial reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the Company’s principal executive and financial officer and effected by the Company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company.
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.
The Company’s management assessed the effectiveness of the Company’s internal control over financial reporting as of the Evaluation Date. In making this assessment, the Company’s management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) Internal Control-Integrated Framework (2013). The COSO framework is based upon five integrated components of control: control environment, risk assessment, control activities, information and communications and ongoing monitoring.
Based on an evaluation under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and Chief Financial Officer, Company management has concluded that the Company’s internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act were ineffective as of the Evaluation Date based on the number of adjustments from the audit., The Company will continue to improve its internal controls, to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

---

ITEM 9B. OTHER INFORMATION
ITEM 9B. OTHER INFORMATION
On July 15, 2023, Wendell Hecker resigned from his role as Chief Financial Officer (“CFO”) position with the Company and was succeeded by Gabrielle Schuster on July 17, 2023. On March 3, 2024, Gabrielle Schuster resigned from her role as the Company’s CFO. Their resignations were not the result of any disagreement with the Company or any other entity or any matter relating to the operations, policies (including accounting or financial policies) or practices of the Company.
On August 14, 2023, Nickolas S. Tabraue, resigned from his role as Chief Compliance Officer position with the Company. His resignation was not the result of any disagreement with the Company or any other entity or any matter relating to the operations, policies (including accounting or financial policies) or practices of the Company.
PART III

---

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE (Restated)
The Company does not, at present, have any employees other than the current officers and directors. We have not entered into any employment agreements, as we currently do not have any employees other than the current officers and directors.
Directors and Executive Officers
Name
Principal Occupation
Age
Director or Officer Since
Giorgio R. Saumat
Chief Executive Officer and Director
Mario G. Tabraue
President and Director
Ernesto Flores
Chief Financial Officer
Christopher Rose
Chief Technology Officer
Jeff P.H. Cazeau
Independent Director
Yovan Sanchez
Director
Emiliano Curia
Independent Director
There are no other people nominated or chosen to become directors or executive officers, nor do we have any employees other than above mentioned officers and directors.
Our directors hold office until the next annual meeting of shareholders and the election and qualification of their successors. Directors receive two thousand dollars per Board of Directors meeting attended for serving on the Board of Directors, in addition to the reimbursement of reasonable expenses incurred in attending meetings if any. Officers are appointed by the board of directors and serve at the discretion of the board. In March 2024, our Board of Directors appointed a new CFO.
Officer and Director Background:
Giorgio R. Saumat -CEO, Director, & Chairman
Mr. Saumat is an investor and entrepreneur with over 20 years of experience investing, operating, and consulting for private businesses and investors. Having graduated from Rutgers University in 2001 with an undergraduate degree in Economics and Political Science, he co-founded CASAU Group as a private equity group specializing in real estate. In 2009 he opened and invested in multiple locations of restaurants in the greater Miami Area, which he sold in 2013. He then founded POINT96 Consulting to assist private businesses and accredited investors in realizing their personal and/or organizational objectives through unique strategic planning.
Mario G. Tabraue - President & Director
Mr. Tabraue worked from 1997 until 2002 assisting with real estate transactions as well as first- and third-party insurance claims at the law firm of Moises Kaba III. During this time, he also free-lanced, creating websites and working with businesses by creating and implementing new processes in accounting and with digital technologies. From 2002 until 2009, Mr. Tabraue worked for Eller-ITO Stevedoring Company at the Port of Miami where he served in operations and logistics, first with simple vessel operations, and, as he demonstrated his skills, advanced to complex operations and finally management of full vessel planning and operations. From 2009 until 2013, Mr. Tabraue worked for Ceres Marine Terminals as an operations manager, where he was given ever increasing responsibilities until, among his duties, were negotiating contract issues with union labor officials and contract negotiations with companies such as Royal Caribbean, Mediterranean Shipping Lines, Hapag-Lloyd and others. In 2013 through 2014 he began working with Zoological Wildlife Foundation, a business founded by his family in 2008. At the Foundation he restructured operations, tour packages, the accounting systems, and fully automated their booking system through the company’s website. Ultimately all internal procedures were automated and made paperless. In 2014 Mr. Tabraue was recruited back to Eller-ITO where he returned as Marine Manager and has advanced to the position of Special Projects Manager. In 2019, he began work for JCR Medical Equipment, serving as the head of finance. In 2020 Mr. Tabraue purchased RxCompoundStore.com with the vision of starting a telemedicine platform to expand the company’s reach and to compete in the online market.
Jeff P.H. Cazeau - Independent Director
Mr. Cazeau is an attorney whose practice areas have included Government Contracts, Lobbying and Municipal Law. Mr. Cazeau currently serves as the City Attorney for the City of North Miami. Prior to becoming City Attorney, Mr. Cazeau assisted clients in obtaining and keeping contracts with federal, state, and local government entities. Mr. Cazeau is experienced in assisting small, minority, and women owned businesses in obtaining various socio-economic certifications such as Disadvantaged Business Enterprise (DBE); Airport Concessions Disadvantaged Business Enterprise (ACDBE) certifications and SBA 8(a). Before attending law school, Mr. Cazeau served nine years as a commissioned officer in the United States Navy. During his naval career he held several positions, including Anti-Submarine Warfare Officer, Legal Officer, and Navigator aboard USS ELLIOT (DD 967), and Politico-Military Affairs Officer at United States Southern Command (SOUTHCOM).
Ernesto Flores - CFO
Mr. Flores is an accomplished financial professional with over a decade of experience and a strong educational background. He holds a Bachelor of Science degree in Accounting from Florida National University and a Master of Science degree in Taxation from Nova Southeastern University. Throughout his career, Mr. Flores has held significant roles in both large corporations and mid-sized organizations, demonstrating adaptability and leadership. At St. George Logistics, he served as Divisional Controller, overseeing financial operations and ensuring regulatory compliance. His four-year tenure at Curated Investments, LLC as Financial Controller highlighted his ability to manage financial functions effectively and drive strategic initiatives. Mr. Flores possesses a diverse skill set, including preparing companies for growth, implementing systems integration, maintaining controllership, managing risk, optimizing inventory control, overseeing P&L management, establishing internal controls, facilitating financial reporting, conducting audits, and driving process improvements.
Christopher Rose CTO
Chris Rose is a dynamic and innovative leader with a diverse background in technology, entrepreneurship, and strategic leadership. In his former leadership role at a Fortune 100 company, Chris established and managed an enterprise-wide automation factory. That factory, comprised of a diverse team across the US, UK, and India, achieved significant milestones, including twenty million dollars in annual transactional cost reduction and the automation of over hundreds business processes.
Chris has always had an entrepreneurial spirit. He brings his passion for, and successful experience with, leading startups to ETST, where he employs technology to achieve tangible business outcomes, predominantly driving operational efficiency and cost savings.
Chris is known for his hands-on approach, collaborative leadership style, and commitment to developing high-performing teams. A Miami native, Chris is also an adventurer who enjoys freediving, spearfishing, and boating, and who carries with him an unwavering optimism. With twenty plus years of technology leadership and exploration behind him, he is uniquely poised to make a significant impact as ETST’s Chief Technology Officer.
Yovan Sanchez - Director
Mr. Sanchez is a seasoned firefighter/paramedic and a driven entrepreneur. With more than two decades of dedicated service in the firefighting and paramedic field, he has been a stalwart in his community. In addition to his public service, Yovan is also a real estate owner and manager in South Florida. In 2011, he took the initiative to establish Hot Box Incubators Corp. Yovan’s commitment to community development extends to supporting youth programs, culminating in the creation of Miami Springs Jiu Jitsu in 2022. Furthermore, he possesses over 20 years of valuable experience in the boat and yacht industry, specializing in identifying opportunities and harnessing them to his advantage. His extensive network of connections across various industries bolsters his ability to make the most of these opportunities.
Emiliano Curia- Director
Dr. Curia is a physical medicine and rehabilitation physician with expertise in musculoskeletal disorders and neurorehabilitation after injuries or illness. He completed his residency at Jackson Memorial Hospital and Larkin Community Hospital, where he also served as Chief Resident. Prior to residency he served as medical research director for multiple pharmaceutical clinical trials and orthopedic technology development and implementation. He participated in multiple community outreach programs and developed quality improvement protocols for underserved populations in Miami Dade county. Dr Curia currently treats patients with musculoskeletal disorders, athletes, and amputees.
Committees of The Board of Directors
The Company is managed under the direction of Giorgio R. Saumat, Mario G. Tabraue, Jeff P.H. Cazeau, Yovan Sanchez and Emiliano Curia.
The Company does not have an executive committee at this time.
The Company has an audit committee of three members of the Board of Directors. Two of the three committee members are independent directors.
Officer’s and Director’s Involvement in Legal Proceedings
No executive Officer or Director of the Company has been convicted in any criminal proceeding (excluding traffic violations) or is the subject of a criminal proceeding that is currently pending. No executive Officer or Director of the Company is the subject of any pending legal proceedings. No Executive Officer or Director of the Company is involved in any bankruptcy petition by or against any business in which they are a general partner or executive officer at this time or within two years of any involvement as a general partner, executive officer, or Director of any business.

---

ITEM 11. EXECUTIVE COMPENSATION
ITEM 11. EXECUTIVE COMPENSATION
Giorgio R. Saumat started as CEO on February 13, 2023, without any compensation until October 1, 2023, when a contract became effective for compensation of twenty one percent of the Company’s monthly revenue within a twelve-month term, paid on the first of the month, based on the preceding month’s revenue, as long as the Company increases its cash position quarter over quarter. In the event that the Company does not increase its cash position, the arrangement must be renegotiated, and there will be no payment at the beginning of the new quarter. Moreover, Mr. Saumat has agreed to waive all rights to back pay and compensation for the work done in the Company prior to September 30, 2023.
Mario G. Tabraue started as President in November 2021, without compensation. On April 1, 2022, Mr. Tabraue received 2,500,000 shares of the Company’s common stock and received $8,000.00 as a signing bonus for all the work done since executing the November 3, 2021 agreement for the purchase of RxCompoundStore and Peak’s Curative. Pursuant to this contract, the Executive was to receive four thousand, three hundred, and thirty-three dollars per month. The frequency of payments was to conform to the Company’s policy of paying its executives biweekly. In addition, the Executive was to be entitled to 50,000 shares each fiscal quarter. On October 10, 2022, Mr. Tabraue’s employment agreement was amended to receive no compensation until October 1, 2023, when a contract became effective for compensation of ten and a half percent of the Company’s monthly revenue within a twelve-month term, paid on the first of the month, based on the preceding month’s revenue, as long as the Company increases its cash position quarter over quarter. In the event that the Company does not increase its cash position, the arrangement must be renegotiated, and there will be no payment at the beginning of the new quarter. Moreover, Mr. Tabraue has agreed to waive all rights to back pay and compensation for the work done in the Company prior to September 30, 2023.
Ernesto Flores was hired as CFO by the company in March 2024, starting with an annual base salary of one hundred sixty thousand dollars, paid biweekly. Additionally, Mr. Flores will receive bonuses upon completing agreed-upon milestones and may be eligible for a year-end discretionary bonus determined by the Chief Executive Officer of the Company.
Christopher Rose was hired as CTO by the company in April 2024 with an annual salary of two hundred seventy thousand dollars paid on a biweekly basis. Additionally, Mr. Rose will receive bonuses upon completing agreed-upon milestones and may be eligible for a year-end discretionary bonus determined by the Chief Executive Officer of the Company.
There are no other employment agreements between the Company and its executive officers or directors. Our executive officers and directors have the responsibility of determining the timing of remuneration programs for key personnel based upon such factors as positive cash flow, shares sales, product sales, estimated cash expenditures, accounts receivable, accounts payable, notes payable, and cash balances. At this time, management cannot accurately estimate when sufficient revenues will occur to implement this compensation, or the exact amount of compensation.
POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE-IN-CONTROL
SEC regulations state that we must disclose information regarding agreements, plans or arrangements that provide for payments or benefits to our executive officers in connection with any termination of employment or change in control of the Company. Such payments are set forth above in the section entitled “Executive Compensation
None of our executive officers or directors received, nor do we have any arrangements to pay out, any bonus, stock awards, option awards, non-equity incentive plan compensation, or non-qualified deferred compensation.
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END
None.
OPTION/SAR GRANTS IN THE LAST FISCAL YEAR
None.
CONSULTING AGREEMENTS WITH OFFICERS AND DIRECTORS
None.
DIRECTOR COMPENSATION
As of October 1, 2023, the Company began compensating each of its members of the Board of Directors two thousand dollars per Board of Directors meeting attended during their term.
INDEMNIFICATION OF DIRECTORS AND OFFICERS
The Company’s officers and directors are indemnified as provided by the Florida Statutes and the Company’s bylaws.
The Company’s bylaws provide that it will advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or officer of the Company, or is or was serving at the request of Earth Science Tech as a director or executive officer of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefore, all expenses incurred by any director or officer in connection with such proceeding upon receipt of an undertaking by or on behalf of such person to repay said amounts if it should be determined ultimately that such person is not entitled to be indemnified under the bylaws or otherwise.
There are no annuity, pension or retirement benefits proposed to be paid to officers, directors, or employees of the corporation in the event of retirement at normal retirement date pursuant to any presently existing plan provided or contributed to by Company.

---

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
As of March 31, 2024, we had outstanding 309,981,819 shares of common stock. Each share of common stock is currently entitled to one vote on all matters put to a vote of our stockholders. The following table sets forth the number of common shares, and percentage of outstanding common shares, beneficially owned as of the date hereof by:
● each person known by us to be the beneficial owner of more than five percent of our outstanding common stock;
● each of our current directors;
● each our current executive officers and any other persons identified as a “named executive” in the Summary Compensation Table above; and
● all our current executive officers and directors as a group.
Beneficial ownership is determined in accordance with the rules of the SEC and includes general voting power and/or investment power with respect to securities. Shares of common stock issuable upon exercise of options or warrants that are currently exercisable or exercisable within 60 days of the record date, and shares of common stock issuable upon conversion of other securities currently convertible or convertible within 60 days, are deemed outstanding for computing the beneficial ownership percentage of the person holding such securities but are not deemed outstanding for computing the beneficial ownership percentage of any other person. Under the applicable SEC rules, each person’s beneficial ownership is calculated by dividing the total number of shares with respect to which they possess beneficial ownership by the total number of outstanding shares. In any case where an individual has beneficial ownership over securities that are not outstanding but are issuable upon the exercise of options or warrants or similar rights within the next 60 days, that same number of shares is added to the denominator in the calculation described above. Because the calculation of each person’s beneficial ownership set forth in the “Percentage Beneficially Owned” column of the table may include shares that are not presently outstanding, the total sum of the percentages set forth in such a column may exceed 100%. Unless otherwise indicated, the address of each of the following persons is 8950 SW 74th CT, Miami, FL 33156, USA, and, based upon information available or furnished to us, each such person has sole voting and investment power with respect to the shares set forth opposite his, her or its name.
Beneficial Owner(1) Common Stock Series B
Preferred Stock
Number of Shares
Beneficially Owned(2)
Percent(3)
5% Stockholders:
Jose Rodriguez (4) 20,500,000
20,500,000 6.61 %
Mario A. Portela (5) 20,500,000
20,500,000 6.61 %
Great Lakes Holdings Group, Inc.(6) 23,000,000
23,000,000 7.42 %
Named Executive Officers and Directors:
Giorgio R. Saumat -Chief Executive Officer, Secretary and Director (7) 119,702,407 1,000,000 119,702,40 38.62 %
Yovan Sanchez (8) 650,000
650,000 0.21 %
Mario G. Tabraue (9) 12,250,000
12,250,000 3.95 %
All executive officers and directors as a group (6 persons)
132,602,407 42.78 %
(1 Except as otherwise indicated, the persons named in this table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws where applicable and to the information contained in the footnotes to this table.
(2) Under SEC rules, a person is deemed to be the beneficial owner of shares that can be acquired by such person within 60 days upon the exercise of options or the settlement of other equity awards.
(3) Calculated on the basis of 309,981,819 shares of common stock outstanding as of March 31, 2024, plus any additional shares of common stock that a stockholder has the right to acquire within 60 days after March 31, 2024. Further, the positions listed are as of the date of this Registration Statement.
(4) Jose Rodriguez received 20,500,000 shares of the Company’s restricted Common Stock on November 8, 2022, through a settlement and release agreement part of the amended Purchase Agreement for the Membership units of both RxCompound and Peaks, see November 8, 2022’s 8-K filing.
(5) Mario A. Portela received 2,750,00 shares of the Company’s restricted Common Stock through a settlement release agreement to satisfy his convertible promissory note, see October 28, 2022’s 8-K filing. On November 8, 2022, Mr. Portela received 17,750,000 shares of the Company’s restricted Common Stock through a settlement and release agreement as part of the amended Purchase Agreement for the Membership units of both RxCompound and Peaks, see November 8, 2022’s 8-K filing.
(6) Great Lakes is owned and controlled by Dr. Issa El-Cheikh.
(7) Giorgio R. Saumat has been a Director of the Company since October 2022 and CEO of the Company since February 2023. Mr. Saumat obtained 62,562,440 shares of the Company’s restricted Common Stock on October 24, 2022, from a settlement and release agreement, see October 28, 2022’s filed 8-K. Mr. Saumat purchased a total of 42,200,000 shares at $0.005 per shares directly from the Company and 1,533,654 shares in the open market between October 2022 and February 2024, all shares obtained by Mr. Saumat are filed via FORM-4 in compliance with the SEC. Additionally, Mr. Saumat received a total of 13,406,313 shares of common stock from converting his two convertible Notes, 5,8020,106 shares at $0.0283 per share on June 5, 2023, and 7,586,207 shares at $0.0290 per share on June 12, 2023.
(8) Yovan Sanchez has been a member of the Board of Directors since November 7, 2023. His 650,000 shares of common stock were obtained through purchasing on the open market between December 2023, and March 2024, all shares obtained by Mr. Sanchez are filed via FORM-4 in compliance with the SEC.
(9) Mario G. Tabraue has been the President and Director of the Company since November 2021. Mr. Tabraue received 2,000,000 shares of the Company’s restricted Common Stock in April 2022 upon executing his employee agreement and 10,250,000 shares of the Company’s restricted Common Stock through a settlement and release agreement as part of the amended Purchase Agreement for the Membership units of both RxCompound and Peaks, see November 8, 2022’s 8-K filing.
Rule 13d-3 under the Securities Exchange Act of 1934 governs the determination of beneficial ownership of securities. That rule provides that a beneficial owner of a security includes any person who directly or indirectly has or shares voting power and/or investment power with respect to such security. Rule 13d-3 also provides that a beneficial owner of a security includes any person who has the right to acquire beneficial ownership of such security within sixty days, including through the exercise of any option, warrant or conversion of a security. Any securities not outstanding which are subject to such options, warrants or conversion privileges are deemed to be outstanding for the purpose of computing the percentage of outstanding securities of the class owned by such person. Those securities are not deemed to be outstanding for the purpose of computing the percentage of the class owned by any other person.
There were no grants of stock options since inception to March 31, 2024. We do not have any long-term incentive plans that provide compensation intended to serve as an incentive for performance.
The Board of Directors of the Company has not adopted a stock option plan. The company has no plans to adopt one but may choose to do so in the future. If such a plan is adopted, this may be administered by the board, or a committee appointed by the board (the “Committee”). The Committee would have the power to modify, extend or renew outstanding options and to authorize the grant of new options in substitution therefore, provided that any such action may not impair any rights under any option previously granted. The Company may develop an incentive-based stock option plan for its officers and directors and may reserve up to 10% of its outstanding shares of common stock for that purpose.

---

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
On November 7, 2023, a voting majority entitled by action without meeting of the Company’s shareholders elected Emiliano Curia as the Company’s Independent Director of the Board. Mr. Curia will receive two thousand dollars per Board of Directors meeting attended and for all services rendered.
EQUITY ISSUANCES TO OFFICERS AND DIRECTORS
None.

---

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.
During the fiscal year ended March 31, 2024, we incurred approximately $65,000 in audit and audit related fees to our principal independent accountants for professional services rendered in connection with the audit of financial statements for the year ended March 31, 2024. We did not incur any other fees or tax-related services fees during that time period.
Assurance Dimensions LLC is the Company’s principal auditing firm for fiscal year ending March 31,2024, which billed the Company $20,000 for audit services during the year. The Company’s Board of Directors has considered whether the provisions of audit services are compatible with maintaining Assurance Dimensions LLC’ independence. The engagement of our independent registered public accounting firm was approved by our Board of Directors prior to the start of the audit of our consolidated financial statements for the year ended March 31, 2024.
R. Bolko, CPA P.A. was the audit firm that performed audit services for year ended March 31, 2023.
The following table represents aggregate fees billed to the Company for the Fiscal Years ended March 31, 2024, and 2023.
Services
Audit fees $ 65,000 $ 10,000
Audit related fees - -
Tax fees 7,500 -
All other fees - -
Total fees $ 72,500 $ 10,000
PART IV

---

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
ITEM 15. EXHIBITS
The following exhibits are incorporated into this Form 10-K Annual Report:
Exhibit
Incorporated by Reference
Filed or Furnished
Number
Exhibit Description
Form
Exhibit
Filing Date
Herewith
31.1
Certification of Chief Executive Officer Pursuant to Exchange Act Rule 13a-14(a) As adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
X
31.2
Certification of Chief Executive Officer Pursuant to Exchange Act Rule 13a-14(a) As adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
X
32.1
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
X
32.2
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
X
101.INS
Inline XBRL Instance Document
X
101.SCH
Inline XBRL Taxonomy Extension Schema
X
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase
X
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase
X
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase
X
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase
X
Cover Page Interactive Data File (embedded within the Inline XBRL document)
X